文献速递前列腺癌男科与性医学

年轻及中年非转移性前列腺癌患者接受雄激素剥夺治疗与痴呆和抑郁风险

Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
PubMed 文献 · Eur Urol Oncol · 2019-10-14

该观察性研究基于TRICARE军事数据库纳入9117例40-64岁局限性前列腺癌患者,比较接受与未接受雄激素剥夺治疗(ADT)者新发痴呆或抑郁的风险。结果显示ADT组抑郁和痴呆发病率均更高,抑郁风险显著增加(HR 2.07,p<0.001),痴呆风险升高接近统计学意义(HR 1.70,p=0.052),且ADT疗程与两种结局呈剂量-反应关系。

要点

  • 40-64岁局限性前列腺癌患者接受ADT与抑郁风险显著升高相关(HR 2.07,p<0.001)。
  • ADT与痴呆风险升高相关但未达统计学显著性(HR 1.70,p=0.052)。
  • ADT使用时长与痴呆或抑郁结局呈剂量-反应关系,长期使用风险最高。

核心结论

  • 在40-64岁非转移性前列腺癌男性中,接受ADT与发生痴呆和抑郁的风险增加相关。
  • 长期使用ADT与神经认知结局的最高风险相关。

研究设计与样本

  • 观察性研究,利用TRICARE军事数据库识别2007至2014年间诊断的9117例40-64岁局限性前列腺癌男性,且无既往神经认知诊断。
  • 采用Kaplan-Meier曲线比较ADT与非ADT组,并对ADT≥12个月的患者进行亚组分析。
  • 使用逆概率治疗加权调整的Cox比例风险回归分析ADT与新发痴呆或抑郁的关联。

主要发现

  • ADT组抑郁发病率为30.2/1000人年,非ADT组为15.8/1000人年。
  • ADT组痴呆发病率为17.9/1000人年,非ADT组为7.5/1000人年。
  • ADT组抑郁风险更高(HR 2.07,p<0.001),痴呆风险亦更高(HR 1.70,p=0.052)。
  • ADT使用时长与痴呆或抑郁结局之间存在剂量-反应关系。

临床怎么用

  • 对40-64岁非转移性前列腺癌患者处方ADT时,应评估并监测抑郁和痴呆风险。
  • 长期使用ADT者可能需更密切关注神经认知结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have found an association between androgen deprivation therapy (ADT) and an increased risk of dementia and depression in elderly men. This association remains controversial, and little is known about the effects of ADT in younger men. OBJECTIVE: To examine the association between the receipt of ADT and these outcomes in young men aged 40-64 yr presenting with nonmetastatic prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: For this observational study, we identified 9117 men aged 40-64 yr diagnosed with localized PCa between 2007 and 2014, without a pre-existing neurocognitive diagnosis, using the TRICARE military database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier curves were fitted to compare ADT versus no ADT. We also performed a subgroup analysis in patients undergoing ADT for ≥12 mo. The association between ADT and new-onset dementia or depression was evaluated using inverse-probability-of treatment-weight-adjusted Cox proportional hazards regression analysis. RESULTS AND LIMITATIONS: Patients receiving ADT had a significantly higher incidence of depression (30.2 vs 15.8 per 1000 person years) and dementia (17.9 vs 7.5 per 1000 person years). The risk of developing either outcome was higher in the ADT cohort (depression: hazard ratio [HR] 2.07, p < 0.001; dementia: HR 1.70, p = 0.052). Additionally, there was a dose-response relationship between the duration of ADT and either outcome. CONCLUSIONS: In our cohort of young men with PCa, the receipt of ADT was associated with an increased risk of developing dementia and depression. Long-term use of ADT was associated with the highest risk of neurocognitive outcomes. PATIENT SUMMARY: In this study, we looked at the risk of dementia and depression in patients <65 yr of age undergoing androgen deprivation therapy (ADT) for prostate cancer. We found that these patients had a higher risk of dementia and depression than those who did not undergo ADT.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tully KH, Nguyen DD, Herzog P, et al. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. 2019. PMID: 31624049. doi:10.1016/j.euo.2019.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。